
|Articles|July 1, 2002
Alefacept response lingers in psoriatic patients
New Orleans - Psoriatic patients achieving >75 percentreduction in PASI score with one course of alefacept (Amevive) followedby treatment-free follow-up maintained >50 percent reduction for at leasteight months.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
The SkinCARE Questionnaire: Assessing the Psychological Dimensions of Skin Health Beyond Disease
5


















